ReviewFrontiers in immunology2024
Immunopathology of lung transplantation: from infection to rejection and vice versa.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Development and Validation of a Computed Tomography-Based Convolutional Neural Network Model for Assisting Donor Lung Acquisition in Lung Transplantation.Journal of imaging informatics in medicine · 2026Article
- Mechanistic analysis of an IRF7-dependent pathway in virus-induced fibrosis in chronic lung allograft dysfunction.EBioMedicine · 2026Article
- Contribution of host-related immune factors to frequency and severity of infections in lung transplant recipients.Respiratory research · 2026Article
- Postoperative Day-28 Neutrophil-to-Lymphocyte Ratio as a Predictor of Early Mortality After Lung Transplantation.Diagnostics (Basel, Switzerland) · 2026Article
- CRISPR/Cas9-mediated B2m knockout paves the way for allogeneic basal cell transplantation.Respiratory research · 2026Article
- B cell-mediated immune reconstitution after lung transplantation: mechanisms, interventions, and prognostic evaluation.Frontiers in immunology · 2026Review
- Pneumonia in lung transplant recipients: the role of donor, recipient, and hospital-acquired microorganisms.Respiratory research & clinical practice · 2026Article
- The Myeloid-T Lymphocyte Axis in Chronic Lung Allograft Rejection: Emerging Insights into the Immune Circuitry Driving Fibrosis.Results and problems in cell differentiation · 2026Review
- Selection Patterns and Outcomes of Kidney Transplantation Versus Dialysis in Lung Recipients with End-Stage Renal Disease: A Single-Center Retrospective-Observational Study.Journal of clinical medicine · 2025Article
- The Role of Microbiology at the 1-Month Surveillance Bronchoalveolar Lavage in the Identification of Complications in the First Year After Lung-Transplantation-A Retrospective Single-Center Experience.Life (Basel, Switzerland) · 2025Article
- Review
- Early rejection management in a heart-lung transplant adolescent under tubeless spontaneous ventilation anesthesia: a case report.Translational pediatrics · 2025Article
- Pharmacodynamics monitoring after lung transplantation.JHLT open · 2025Review
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Primary herpes Simplex Virus type 1 pneumonitis in a patient after bilateral lung transplantation.IDCases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation offers a lifesaving option for patients with end-stage lung disease, but it is marred by a high risk of post-transplant infections, particularly involving multidrug-resistant bacteria, Cytomegalovirus, and fungal pathogens. This elevated infection rate, the highest among solid organ transplants, poses a significant challenge for clinicians, particularly within the first year post-transplantation, where infections are the leading cause of mortality. The direct exposure of lung allografts to the external environment exacerbates this vulnerability leading to constant immune stimulation and consequently to an elevated risk of triggering alloimmune responses to the lung allograft. The necessity of prolonged immunosuppression to prevent allograft rejection further complicates patient management by increasing susceptibility to infections and neoplasms, and complicating the differentiation between rejection and infection, which require diametrically opposed management strategies. This review explores the intricate balance between preventing allograft rejection and managing the heightened infection risk in lung transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.